Fulgent Genetics (FLGT) Long-Term Investments (2016 - 2026)

Fulgent Genetics has reported Long-Term Investments for 11 years, with the latest figure at $294.3 million in Q2 2026.

• Quarterly Long-Term Investments fell 39.25% year-over-year to $294.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $294.3 million (down 39.25% YoY) and the FY2025 annual result came in at $369.3 million, down 35.26% from the prior year.
• Long-Term Investments retreated to $294.3 million in Q2 2026 per FLGT's latest filing, from $328.3 million in the prior quarter.
• Over five years, Long-Term Investments peaked at $602.2 million in Q3 2024 and troughed at $294.3 million in Q2 2026.
• A 5-year average of $431.5 million and a median of $413.7 million in 2022 frame the typical range for Long-Term Investments.
• The sharpest annual moves came in 2022 and 2026: Long-Term Investments soared 71.47% in 2022, then slumped 39.25% in 2026.
• Over 5 years, Long-Term Investments stood at $326.6 million in 2022, then climbed by 29.67% to $423.6 million in 2023, then jumped by 34.65% to $570.4 million in 2024, then tumbled by 35.26% to $369.3 million in 2025, then declined by 20.3% to $294.3 million in 2026.
• According to Business Quant data, Long-Term Investments over the past three periods registered $294.3 million, $328.3 million, and $369.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.